Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small molecules for small minds? The case for biologic pharmaceuticals.

Steven J Projan1, Davinder Gill, Zhijian Lu

  • 1Department of Protein Technologies, Wyeth Research, Cambridge, MA 02140, USA. projans@wyeth.com

Expert Opinion on Biological Therapy
|July 23, 2004
PubMed
Summary

Biologic pharmaceuticals, including therapeutic proteins, offer advantages over small molecule drugs due to lower toxicity and targeted applications. Continued advancements in biologic technology promise significant industry growth in the coming decade.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Covalent inhibitors of human papillomavirus type 16 E6 protein restore p53 function and suppress growth of HPV-driven tumors in vivo.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

The stem-derived bioactive fraction of Syringa oblata Lindl. Ameliorates insomnia via cAMP signaling-mediated regulation of neurotransmission, oxidative stress, and inflammation: A multi-omics study.

Fitoterapia·2026
Same author

Combatting antimicrobial-resistant Neisseria gonorrhoeae: new antibiotics and the pipeline of antigonococcal therapeutics.

Current opinion in infectious diseases·2025
Same author

Structural evolution of β-lactoglobulin under intensified magnetic fields.

Food research international (Ottawa, Ont.)·2025
Same author

Pharmacokinetics, tissue distribution, in vivo metabolism and liver microsomal metabolism of GK-A, GK-2 and Eucomic acid in rats were studied by liquid chromatography-tandem mass spectrometry and mass spectrometry imaging of Ginkgo semen extract.

Journal of ethnopharmacology·2025
Same author

Covalent Inhibition of the Human Papillomavirus Type 16 E6 Protein Restores p53 and Suppresses HPV-Driven Tumorigenesis.

bioRxiv : the preprint server for biology·2025

Area of Science:

  • Biopharmaceutical development
  • Drug discovery and manufacturing
  • Protein therapeutics

Background:

  • Biologic pharmaceuticals are increasingly utilized, surpassing small molecule therapeutics in market share and clinical applications.
  • The biopharmaceutical sector is in its early stages, with expectations of reduced development times and manufacturing costs as the field matures.
  • While specific toxicity mechanisms, such as antibody responses to therapeutic proteins, require further research, proteins generally exhibit less idiosyncratic toxicity than small molecule drugs.

Purpose of the Study:

  • To compare the advantages and disadvantages of biologic pharmaceuticals versus small molecule therapeutics.
  • To highlight the growth potential and future trends in protein pharmaceutical technology.
  • To discuss the clinical utility and manufacturing aspects of biologic drugs.

Related Experiment Videos

Main Methods:

  • Comparative analysis of biologic and small molecule drug characteristics.
  • Review of current trends in pharmaceutical development and manufacturing.
  • Assessment of therapeutic targeting capabilities for different drug modalities.

Main Results:

  • Biologics demonstrate lower idiosyncratic toxicity compared to small molecules.
  • Proteins excel in targeting protein-protein interactions and cell surface features, particularly in oncology.
  • Small molecules are less suitable for intercellular process targeting compared to biologics.

Conclusions:

  • Biologic pharmaceuticals represent a significant growth area for the pharmaceutical industry over the next decade.
  • Advancements in protein pharmaceutical technology are expected to further enhance their clinical utility and market position.
  • The unique strengths of biologics in targeted therapies outweigh their limitations in specific applications.